Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: An appraisal

被引：19

作者：

Wiwanitkit V. ^{[1
]}

机构：

[1] Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University

来源：

Archives of Gynecology and Obstetrics | 2006年 / 273卷 / 6期

关键词：

Plasminogen activator inhibitor-1; Polymorphism; Pre-eclampsia;

D O I：

10.1007/s00404-005-0117-8

中图分类号：

学科分类号：

摘要：

Aim: Plasminogen activator inhibitor-1 (PAI-1) is an important inhibitor of the fibrinolytic system, so it is biologically plausible that elevated levels could suppress fibrinolysis and result in an increased risk of thrombosis. There is considerable controversy regarding the clinical role of PAI-1 4G/5G polymorphism as a risk factor of pre-eclampsia. Here, the author performs a summative analysis on the recent previous reports on the PAI-1 4G/5G and its correlation to pre-eclampsia. Method: The metanalysis was performed in order to assess the correlation between the pattern of PAI-1 4G/ 5G polymorphism and pre-eclampsia. From the available six case-control studies, 880 patients and 810 controls are evaluated. Results: The overall frequencies of 4G allele for the patients and controls are 49.9 and 44.4, respectively. According to this study, 54.9% of subjects with 4G allele have pre-eclampsia while 43.1% of subjects without 4G allele have pre-eclampsia. From overall risk estimation, the subjects with 4G alleles have 1.27 times higher risk to pre-eclampsia. Conclusion: According to this analysis, the author proposes that the pattern of PAI-1 4G/5G polymorphism might represent a useful marker of increased risk for pre-eclampsia. In addition, the lack of association between pattern of PAI-1 4G/5G and ethnicity of the patients can be demonstrated in this study. © Springer-Verlag 2006.

引用

页码：322 / 324

页数：2

共 14 条

[1]

Francis C.W., Plasminogen activator inhibitor-1 levels and polymorphisms, Arch Pathol Lab Med, 126, pp. 1401-1404, (2002)

[2]

Banfi C., Mussoni L., Tremoli E., PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms, Minerva Endocrinol, 27, pp. 181-191, (2002)

[3]

Nordt T.K., Lohrmann J., Bode C., Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis, Thromb Res, 103, 1 SUPPL., (2001)

[4]

Said J., Dekker G., Pre-eclampsia and thrombophilia, Best Pract Res Clin Obstet Gynaecol, 17, pp. 441-458, (2003)

[5]

Hakli T., Romppanen E.L., Hiltunen M., Helisalmi S., Punnonen K., Heinonen S., Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia, Genet Test, 7, pp. 265-268, (2003)

[6]

Yamada N., Arinami T., Yamakawa-Kobayashi K., Watanabe H., Sohda S., Hamada H., Kubo T., Hamaguchi H., The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia, J Hum Genet, 45, pp. 138-141, (2000)

[7]

Pegoraro R.J., Hira B., Rom L., Moodley J., Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in Black South Africans with preeclampsia, Acta Obstet Gynecol Scand, 82, pp. 313-317, (2003)

[8]

Tempfer C.B., Jirecek S., Riener E.K., Zeisler H., Denschlag D., Hefler L., Husslein P.W., Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: A pilot study, J Soc Gynecol Investig, 11, pp. 227-231, (2004)

[9]

Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., Haites N.E., Wilson B.J., Watson M.S., Greaves M., Vickers M.A., Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: Results from a large population-based study and systematic review, Thromb Haemost, 87, pp. 779-785, (2002)

[10]

Fabbro D., D'Elia A.V., Spizzo R., Driul L., Barillari G., Di Loreto C., Marchesoni D., Damante G., Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia, Gynecol Obstet Invest, 56, pp. 17-22, (2003)

← 1 2 →